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Background
Allergy is an increasing autoimmune disease in the devel-
oped world. Current consensus is that allergy is the result
of a misdirected immune response directed towards ‘see-
mingly innocuous antigens’. Many of the allergens have
similarities with parasite proteins and it is generally
accepted that the IgE (Immunoglobulin E) response is a
normal defense mechanism against parasitic infestations.
The conventional treatment of allergy is through pharma-
cotherapy where corticosteroids are used to reduce the
expression of inflammatory proteins; although effective,
they do not combat the underlying cause of allergy. Novel
immunotherapeutic treatments have been developed that
immunize sufferers with anti-IgE antibodies, but this pas-
sive immunization strategy is only temporary, and patients
need to return for follow-up injections.
Methods
This project reports the development of an active anti-
allergy immunotherapy. The synthetic peptide 2Fcε2-3,
derived from human IgE, was injected into rats, and fol-
lowed up by a boost with a chimeric human-dog-human
IgE, in an attempt to direct the immune system and
develop polyclonal antibodies that target a certain epitope
in the IgE antibody which would lead to the removal of
serum and FcεRI receptor bound IgE.
Results
The experiment resulted in a rat serum with strong anti-
body titer targeting the 2Fcε2-3 peptide, this serum was
also found to target native human IgE, as well as the dog
and the horse native IgE antibody. Further analysis
showed that the serum antibodies cross linked receptor
bound IgE and resulted in cell degranulation and media-
tor release.
Conclusions
The immunization strategy was successful but did not fully
work as predicted. The study does, however, lay significant
foundations for future potential anti-allergy vaccine
designs.
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